<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01162733</url>
  </required_header>
  <id_info>
    <org_study_id>30029</org_study_id>
    <nct_id>NCT01162733</nct_id>
  </id_info>
  <brief_title>Loading Vancomycin Doses in the Emergency Department</brief_title>
  <acronym>Loaded</acronym>
  <official_title>A Randomized Prospective Study of Vancomycin Dosing in the Emergency Department: Will a Loading Dose of 30mg/kg Lead to a More Rapid Attainment of Therapeutic Levels?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Christiana Care Health Services</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Christiana Care Health Services</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In 2008, our ED administered an average of 245 doses of vancomycin per month. Currently there
      is no consistency in the ED practice in regards to vancomycin dosing. In 2009, the IDSA put
      forth new recommendations for vancomycin dosing in order to achieve therapeutic levels more
      rapidly. It has been hypothesized that if therapeutic levels are reached more rapidly then
      patients will in turn have better clinical outcomes and that the development of resistant
      organisms will be decreased. Methicillin resistant Staphylococcus aureus (MRSA) has emerged
      as one of the most deadly pathogens that are currently plaguing our patient population.
      Vancomycin is one of only a few antibiotics that are effective for treating MRSA. It is
      imperative that the ED physicians consistently and correctly dose vancomycin in order to give
      the patients the best chance to fight infection while helping to prevent further resistance
      in this already highly resistant organism. It is believed this study will reveal that the new
      dosing recommendations by the IDSA will lead to the achievement of therapeutic levels more
      rapidly. This information will in turn help to convince ED physicians that a change in
      current clinical practice is warranted and ultimately lead to better clinically outcomes for
      the patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recently, the Infectious Disease Society of America (IDSA) has released new dosing
      recommendations for intravenous (IV) vancomycin. These new recommendations suggest
      administering an initial dose of 25-30 mg/kg of vancomycin as opposed to 10-15 mg/kg which is
      more traditionally done. Currently in the Emergency Department (ED) some practitioners are
      using the new IDSA dosing recommendations for vancomycin, while other practitioners have not
      changed their clinical practice. There is currently little data available to suggest that
      implementing these new vancomycin dosing regimens in the ED will achieve therapeutic
      vancomycin levels more rapidly than our traditional dosing practice.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants First Achieving Therapeutic Levels at 36 Hours</measure>
    <time_frame>36 hours</time_frame>
    <description>The objective is to determine if therapeutic levels were reached more rapidly with the implementation of an initial vancomycin loading dose of 30 mg/kg as compared to 15mg/kg.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants First Achieving Therapeutic Levels at 12 Hours</measure>
    <time_frame>12 hours</time_frame>
    <description>Percentage of patients reaching a therapeutic level defined as greater than 15 mcg/mL</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">99</enrollment>
  <condition>Infectious Disease</condition>
  <arm_group>
    <arm_group_label>Study Drug 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vancomycin 15mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Drug 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vancomycin 30mg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin</intervention_name>
    <description>15mg/kg</description>
    <arm_group_label>Study Drug 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin</intervention_name>
    <description>30mg/kg</description>
    <arm_group_label>Study Drug 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years of age

          -  Treated in Christiana Emergency Department

          -  Receiving Vancomycin for an infection or presumed infection

          -  Being admitted to Christiana Hospital

          -  Planned continued use of Vancomycin after admission.

        Exclusion Criteria:

          -  Less than 18 years of age

          -  Weight greater than 120 kg.

          -  Concurrent use of aminoglycosides or acyclovir

          -  Sepsis patients being admitted to ICU with presumed diagnosis of pneumonia

          -  Patients currently undergoing dialysis

          -  Pregnant or breast feeding

          -  No plan to continue Vancomycin after admission.

          -  Creatinine clearance less than 50ml/min.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian Levine, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Christiana Care Health Services</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chrisitana Care Health System-Christiana Hospital</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2010</study_first_submitted>
  <study_first_submitted_qc>July 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2010</study_first_posted>
  <results_first_submitted>September 23, 2013</results_first_submitted>
  <results_first_submitted_qc>March 12, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 13, 2014</results_first_posted>
  <last_update_submitted>March 12, 2014</last_update_submitted>
  <last_update_submitted_qc>March 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vancomycin</keyword>
  <keyword>Therapeutic Levels</keyword>
  <keyword>Infectious Disease</keyword>
  <keyword>Recommendations</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emergencies</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Study Drug 1</title>
          <description>Vancomycin 15mg/kg
Vancomycin : 15mg/kg</description>
        </group>
        <group group_id="P2">
          <title>Study Drug 2</title>
          <description>Vancomycin 30mg/kg
Vancomycin : 30mg/kg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Study Drug 1</title>
          <description>Vancomycin 15mg/kg
Vancomycin : 15mg/kg</description>
        </group>
        <group group_id="B2">
          <title>Study Drug 2</title>
          <description>Vancomycin 30mg/kg
Vancomycin : 30mg/kg</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="49"/>
            <count group_id="B2" value="50"/>
            <count group_id="B3" value="99"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Greater than 18 years of age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants First Achieving Therapeutic Levels at 36 Hours</title>
        <description>The objective is to determine if therapeutic levels were reached more rapidly with the implementation of an initial vancomycin loading dose of 30 mg/kg as compared to 15mg/kg.</description>
        <time_frame>36 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Drug 1</title>
            <description>Vancomycin 15mg/kg
Vancomycin : 15mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Study Drug 2</title>
            <description>Vancomycin 30mg/kg
Vancomycin : 30mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants First Achieving Therapeutic Levels at 36 Hours</title>
          <description>The objective is to determine if therapeutic levels were reached more rapidly with the implementation of an initial vancomycin loading dose of 30 mg/kg as compared to 15mg/kg.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants First Achieving Therapeutic Levels at 12 Hours</title>
        <description>Percentage of patients reaching a therapeutic level defined as greater than 15 mcg/mL</description>
        <time_frame>12 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Drug 1</title>
            <description>Vancomycin 15mg/kg
Vancomycin : 15mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Study Drug 2</title>
            <description>Vancomycin 30mg/kg
Vancomycin : 30mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants First Achieving Therapeutic Levels at 12 Hours</title>
          <description>Percentage of patients reaching a therapeutic level defined as greater than 15 mcg/mL</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Study Drug 1</title>
          <description>Vancomycin 15mg/kg
Vancomycin : 15mg/kg</description>
        </group>
        <group group_id="E2">
          <title>Study Drug 2</title>
          <description>Vancomycin 30mg/kg
Vancomycin : 30mg/kg</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>New onset Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic Reaction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Deb Marco</name_or_title>
      <organization>Christiana Care Health System</organization>
      <phone>302 733-4130</phone>
      <email>dmarco@christianacare.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

